Exscientia
UK AI-drug-design pioneer. Merger-completed with Recursion Pharmaceuticals in 2024.
- Location
- Oxford, United Kingdom
- Stage
- Merged 2024
- Founded
- 2012
- Category
- Other
- Funding
- VC-backed
- Team
- 501-1000
Funding figures as of Jul 2025 · not independently verified
Founders of Exscientia
- Andrew Hopkins
Investors backing Exscientia
- SoftBank
- Novo Holdings
Frequently asked questions
What does Exscientia do?
UK AI-drug-design pioneer. Merger-completed with Recursion Pharmaceuticals in 2024.
Where is Exscientia based?
Exscientia is based in Oxford, United Kingdom.
When was Exscientia founded?
Exscientia was founded in 2012.
How much has Exscientia raised?
Exscientia is vc-backed. Funding details have not been disclosed.
Who founded Exscientia?
Exscientia was founded by Andrew Hopkins.
Who has invested in Exscientia?
Exscientia is backed by SoftBank, Novo Holdings.
How Exscientia would pitch themselves
○ Auto-generated01Target customer
Precision-designed drugs — the core audience Exscientia's product is built around.
02Problem they solve
UK AI-drug-design pioneer. Merger-completed with Recursion Pharmaceuticals in 2024. The category has historically been served by tools that miss the modern workflow this product is built around.
03Key differentiator
Exscientia differentiates on pharmatech for precision-designed drugs. Backed by SoftBank + Novo Holdings — the company has resources + validation to compound this thesis. Founded by Andrew Hopkins.
04Go-to-market strategy
Combined sales + product-led growth approach typical for Other companies at this stage — direct sales for higher-ACV deals, self-serve for SMB adoption, and content + community for top-of-funnel.